Skip to main content


Fig. 4 | BMC Neurology

Fig. 4

From: Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study

Fig. 4

Proportion with EDSS progression at each year by T1 Gd + lesions at 6 months. a Placebo/delayed treatment group; b IFN β-1a 22 μg SC tiw group; c IFN β-1a 44 μg SC tiw group. There was a significant difference in the number of patients who had T1 Gd + lesions at 6 months and who experienced confirmed disability progression at 4 years in the IFN β-1a 44 μg SC tiw group, albeit in a small number of patients (n = 9). No statistically significant differences were seen in the placebo/delayed treatment or IFN β-1a 22 μg SC tiw groups. Values were based on logistic regression model adjusting for number of relapses within the previous 2 years, age, baseline EDSS score, and baseline T1 Gd + lesions. p values were calculated for the predictive effect of T1 Gd + lesions. *p < 0.05. EDSS: Expanded Disability Status Scale; Gd+: gadolinium-enhancing; IFN β-1a: interferon beta-1a; SC: subcutaneously; tiw: three times weekly

Back to article page